Generation of T cell responses against broad KRAS hotspot neoantigens for cell therapy or TCR discovery
Brandon Conn(BioNTech (United States)), Vikram R. Juneja(Takara (United States)), Marit M. van Buuren(The Netherlands Cancer Institute), Jared L. Dietze(BioNTech (United States)), Iraís Ortiz-Caraveo(BioNTech (United States)), Kendra C. Foley(BioNTech (United States)), Margaret Hallisey(Dana-Farber Cancer Institute), Christina Yee(Boston Children's Hospital), Jaewon Choi(BioNTech (United States)), Richard B. Gaynor(BioNTech (United States))
Cited by 5
Related Papers
Therapeutic potential of inhibition of the NF-κB pathway in the treatment of inflammation and cancer
|Journal of Clinical Investigation|2001|1.6k
PD-L1 on tumor cells is sufficient for immune evasion in immunogenic tumors and inhibits CD8 T cell cytotoxicity
|The Journal of Experimental Medicine|2017|872
Tumor Exome Analysis Reveals Neoantigen-Specific T-Cell Reactivity in an Ipilimumab-Responsive Melanoma
|Journal of Clinical Oncology|2013|799